WJPPS Citation

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • New Impact Factor
  • WJPPS Impact Factor has been Increased to 8.025 for Year 2024.

  • WJPPS: MARCH ISSUE PUBLISHED
  • March Issue has been successfully launched on 1 March 2024.

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Scope Indexed
  • WJPPS is indexed in Scope Database based on the recommendation of the Content Selection Committee (CSC).

Abstract

IMPORTANCE OF PEDIATRIC PRODUCT DEVELOPMENT AND AN OVERVIEW ON REGULATORY EXPECTATIONS, REQUIREMENTS AND PROCEDURES

M. Lakshmi Kanth* and Chung Hyun Song

ABSTRACT

In the advanced regulatory environment all competent regulatory agencies grant approval to medications for use in the patients when those have been studied for sufficient and acceptable safety and efficacy which demonstrate the benefits of usage are higher than the expected risks for which alternate treatments are available. Several medical communities have expressed increased concern that the drugs are being used widely in children despite the fact that, in most cases, information about the effects of these products in children is absent or insufficient. In response to this concern, the regulatory agencies have undertaken a number of initiatives to address the problem of inadequate pediatric testing and pediatric use information in drug, biological and medical device labeling. In order to promote the development of medications for pediatric patients national regulatory agencies have enacted different mandatory legislations and published guidanceā€Ÿs explaining the procedures to follow for obtaining required approvals which lead to grant of incentives. The purpose of this article is to describe a concise overview about the regulatory initiatives made by regulatory agencies [United States Food and Drug Administration (U.S. FDA) and European Medical Agency (EMA)] to promote studies on pediatric population for the products available in market and under development products, regulatory agencies expectations, requirements and role of international collaboration in achieving the goal to generate safety and efficacy information of drugs for safe usage in pediatric population.

Keywords: Pediatric, PSP, PREA, PUMA, BPCA and FDASIA.


[Download Article]     [Download Certifiate]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More